Search Results for "Where To Buy Pirfenidone"

07:44 EST 2nd March 2015 | BioPortfolio

Matching Channels


Matching News

FDA Approves Esbriet (pirfenidone) for Idiopathic Pulmonary Fibrosis

October 15, 2014 -- The U.S. Food and Drug Administration today approved Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is a condition i...

FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States

Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) in the United States. IPF is a fatal di...

Real world data supports InterMune's IPF drug

New pooled analyses of data from phase 3 trials presented by InterMune shows that its treatment for idiopathic pulmonary fibrosis (IPF) pirfenidone has long-lasting benefits for patients.The data come...

Roche buying InterMune for $8.3B

Roche (SIX:ROG; OTCQX:RHHBY) will acquire InterMune Inc. (NASDAQ:ITMN) for $74 per share, or about $8.3 billion in cash. The offer is a 63% premium to InterMune's $45.49 closing price on Aug. 12, befo...

InterMune boosted by pirfenidone data

InterMune boosted by pirfenidone data

Roche to acquire InterMune for US$8.3bn

Will expand its respiratory product portfolio with the addition of idiopathic pulmonary fibrosis treatment pirfenidone

Idiopathic pulmonary fibrosis drugs from Roche, Boehringer win FDA approval

The FDA has approved Roche's Esbriet, or pirfenidone, and Boehringer Ingelheim's Ofev, or nintedanib, as treatments for idio -More- 

Roche's pirfenidone bet validates Shanghai Genomics' venture

When Wu Jun co-founded Shanghai Genomics in 2001, he was looking for new drugs to commercialize in China five to 10 years into the future.

Matching PubMed Articles

Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS.

A rapid, sensitive and selective ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of pi...

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Pirfenidone, an oral anti-inflammatory, antifibrotic agent with activity in idiopathic pulmonary fibrosis, may mediate anti-tumor activity in neurofibromatosis type 1 (NF1) and plexiform neurofibromas...

Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis.

Nintedanib and Pirfenidone. New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions.

Update in Diffuse Parenchymal Lung Disease 2013.

The period covered by this update can be considered as the most exciting period in idiopathic pulmonary fibrosis (IPF) research. It started with the identification of genetic variants that are associa...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement